Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of
repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients with
neovascular age-related macular degeneration